"uuid:ID","instanceType","id","rationale","versionIdentifier"
"e95bf07b-9f4b-45a4-88fb-7534f38a4798","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
